Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 5, 2006, Pages 647-653

  Okusaka, Takuji ^a   Ishii, Hiroshi ^b   Funakoshi, Akihiro ^c   Yamao, Kenji ^d   Ohkawa, Shinichi ^e   Saito, Soh ^f   Saito, Hiroshi ^g   Tsuyuguchi, Toshio ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g Yamagata Prefectural Central Hospital   (Japan)

^h CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; Clinical trial; Gallbladder cancer; Gemcitabine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; BILIARY TRACT INFECTION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATEMESIS; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; HYPONATREMIA; LEUKOPENIA; MALE; MEDICAL ASSESSMENT; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; OCCULT BLOOD; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; STOMACH MUCOSA LESION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREMIA;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE;

EID: 32544450658     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0095-3     Document Type: Article

References (41)

1. Aabo K, Pedersen H, Rorth M (1985) Cisplatin in the treatment of advanced gastric carcinoma: a phase II study. Cancer Treat Rep 69:449-450
2. Agelaki S, Papakostas P, Stathopoulos G, Aravantinos G, Kalbakis K, Sarra E et al (1999) Phase II study of docetaxel with G-CSF support as first-line treatment for unresectable or advanced biliary tract carcinoma: a multicenter phase II trial. Proc Am Soc Clin Oncol 18:276a (Abstract No: 1058)
3. Arroyo G, Gallardo J, Rubio B, Orlandi L, Yañez M, Gamargo C et al (2001) Gemcitabine (GEM) in advanced biliary tract cancer (ABTC). Experience from Chile and Argentina in phase II trials. Proc Am Soc Clin Oncol 20:157a (Abstract 626)
4. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
5. Chen JS, Lin YC, Jan YY, Liau CT (2001) Mitomysin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Durgs 12:339-343
6. Davis HL Jr, Ramirez G, Ansfield FJ (1974) Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193-197
7. Dobrila-Dintinjana R, Kovac D, Depolo A, Uravic M, Dintinjana M (2000) Gemcitabine in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer. Am J Gastroenterol 95:2476
8. Eng C, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT et al (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 276:565-569
9. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F et al (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653-656
10. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T et al (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumors. Eur J Cancer 31A:1594-1598
11. Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965-969
12. Fishkin P, Alberts S, Mahoney M, Sargent D, Goldberg R, Burgart L et al (2001) Irinotecan in patients with advanced gallbladder carcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 20:155a (Abstract No: 618)
13. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023-2032
14. Gebbia V, Giuliani F, Verderame F, Boerellino N, Mauceri G, Tirrito M, et al (2001) Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19:4089-4091
15. Harvey JH, Smith FP, Schein PS (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM in carcinoma of the biliary tract. J Clin Oncol 2:1245-1248
16. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2x,2x-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
17. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG et al (2004) Gemcitabine-associated thrombotic microangiopathy. Cancer 100:2664-2670
18. Ikeda M, Okusaka T, Ueno H, Furuse J, Ishii H, Morizane C, et al (2004) Phase II study of UFT for advanced extra- and intrahepatic cholangiocarcinoma (in Japanese). J Jpn Biliary Assoc 18:421
19. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ (1996) Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306-2310
20. Kajanti M, Pyrhonen S (1994) Epribicin-sequential methotrexate-5- fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 17:223-226
21. Kubicka S, Tietze MK, Rudolph L, Manns MP (1999) Phase II study of gemcitabine in patients with nonresectable cancer of the biliary system. Eur J Cancer 35(suppl 4):S151 (Abstract 559)
22. Kuroishi T, Hirose K, Tajima K, Tominaga S (1999) Prediction of cancer death in Japan. In: Tominaga S, Oshima A, Kuroishi T, Aoki K, (eds) Cancer statistics-1999 (in Japanese). Shinohara Shuppan, Tokyo , pp 171-86
23. Lozano R, Patt Y, Hassan M, Frome A, Vauthey J, Ellis L et al (2000) Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer). Proc Am Soc Clin Oncol 19:264a (Abstract No: 1025)
24. Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C, Glasmacher A (1998) A phase II trial of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 21:232-234
25. Ministry of Health, Labour and Welfare. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Vital Statistics of Japan 2002 (in Japanese)
26. Morizane C, Okada S, Okusaka T, Ueno H, Saisho T (2003) Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology 64:475-476
27. National Cancer Institute (1999) Common Toxicity Criteria (version 2). Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda
28. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, et al (2002) Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J cancer 87:702-704
29. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K et al (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51:515-517
30. Okusaka T (2002) Chemotherapy for biliary tract cancer in Japan. Semin Oncol 29:51-53
31. Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K et al (2001) First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 37:1833-1838
32. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, et al (2001) Phase II trail of cisplatin, interferon α-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7:3375-3380
33. Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM et al (1999) Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22:78-81
34. Penz M, Kornek GV, Raderer M, Ulroch-Pur H, Fiebiger W, Lenauer A et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183-186
35. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinländer GS, Bareck E, et al (1999) Two consecutive phase II studies of 5-fluorouracil/leucovorin/ mitomycin C and of gemcitabine in patients with advanced biliary tract cancer. Oncology 56:177-180
36. Sanz-Altamira PM, Ferrante K, Jenkins R, Lewis WD, Huberman MS, Stuart KE (1998) A phase II trial fo 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82:2321-2325
37. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH et al (1993) Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EO-RTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 4:607-609
38. Taieb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T et al (2002) Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13:1192-1196
39. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T (1994) Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 51:396-400
40. Valencak J, Kornek GV, Raderer M, Ulrichi-Pur H, Krauss G, Greul R et al (1999) Gemcitabine for the treatment of advanced biliary tract carcinomas: Evaluation of two different dose regimens. Onkologie 22:498-501
41. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Offset Publication 48. Geneva: World Health Organization